Evrys Bio

Executive Summary

Evrys Bio is a private, early-stage biotechnology company founded in 2021 and headquartered in Cambridge, Massachusetts. The company is developing first-in-class, small-molecule therapies that target host cell pathways to treat a broad spectrum of viral infections, with the goal of overcoming drug resistance commonly associated with direct-acting antivirals. Its lead program, EV-100, is a clinic-ready asset designed for proof-of-concept studies. Evrys Bio leverages a proprietary platform that identifies host factors essential for viral replication, enabling the development of antiviral candidates with high genetic barriers to resistance. The company's approach has the potential to address multiple viral threats, including those for which no effective treatments currently exist. Evrys Bio is at a critical juncture as it prepares to advance EV-100 into clinical development. The company has not yet disclosed specific dosing timelines, but its clinic-ready designation suggests near-term initiation of Phase 1 trials. Given the broad applicability of host-targeted antivirals and the growing need for novel antiviral strategies post-pandemic, Evrys Bio holds significant promise. However, as a private company with no publicly available financial or pipeline data beyond EV-100, its risk profile is elevated. Success will depend on securing funding, executing clinical development, and demonstrating favorable safety and efficacy in early studies.

Upcoming Catalysts (preview)

• Q4 2026Initiation of Phase 1 clinical trial for EV-10070% success
• Q2 2026Announcement of Series A or B financing round60% success
• Q3 2026Release of preclinical proof-of-concept data for EV-100 in a viral indication75% success